Figure 6.

In vivo administration of P-1257 in combination with Trastuzumab inhibits cell proliferation and induces necrosis. (A and B, left panels) JIMT-1 and MCF7: proliferation index, using the anti-ki-67 monoclonal antibody (clone MIB-1), variance of Trastuzumab resistant JIMT-1 and MCF7 BC engrafts as detected by the Bonferroni test. Ki-67 proliferation index, expressed as mean percentage, in engrafts untreated, electroporated and treated with T alone compared with engrafts treated with P-1257 or P-1257 plus T (P<0.0001). (A and B, a/a-d and b/a-d, right panels) Two immunohistochemical explicative panels are provided. Pictures show that the proliferation index is higher (73% a-a; b-a) and the necrosis, as detected by hematoxylin-eosin colorimetric assay, is lower (a-c; b-c) in untreated mice than in 1257+Trastuzumab treated mice (29% A-b; B-b and A-d; B-d), respectively. Scale bar=30 μ